NCT07167966PHASE2NOT_YET_RECRUITING

Alzheimer's Tau Platform: Regimen A - AADvac1

Alzheimer's Tau Platform (ATP): Regimen Specific Appendix for AADvac1

Sponsor: Paul S. Aisen + Axon Neuroscience SE, University of California, San Francisco

No open prediction endpoints

Endpoints are classified and published by ProgramSignal analysts.

Request endpoint coverage

Key Facts

Study type

INTERVENTIONAL

Conditions

Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer Disease

Interventions

AADvac1, Donanemab

Enrollment

450 participants

Primary completion

Aug 2028

Study completion

Aug 2028

First posted

Sep 2025

Last updated

Apr 2026

Primary Endpoints (CT.gov)

Reduction of brain tau deposition as measured by tau positron emission tomography (PET)

Time frame: 0, 6, 18 and 30 months

Secondary Endpoints

Disease progression as measured by plasma biomarkers

Eligibility Criteria

Inclusion Criteria: * No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT06957418). Exclusion Criteria: * No additional exclusion criteria beyond the exclusion criteria specified in the Master Protocol (NCT06957418).

✦ Analyst Commentary

Expert commentary on why this trial matters and what to watch for.

Request coverage →

Source

Open on ClinicalTrials.gov